<DOC>
	<DOC>NCT02082197</DOC>
	<brief_summary>This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.</brief_summary>
	<brief_title>An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<criteria>Low testosterone Normal testosterone levels Elevated Prostatic Specific Antigen (PSA) History of breast or prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>low testosterone</keyword>
</DOC>